Disrupted BRCA1-PALB2 interaction induces tumor immunosuppression and T-lymphocyte infiltration in HCC through cGAS-STING pathway

Hepatology. 2023 Jan 1;77(1):33-47. doi: 10.1002/hep.32335. Epub 2022 Feb 15.

Abstract

Background and aims: BRCA1 (BRCA1 DNA repair associated) and PALB2 (partner and localizer of BRCA2) interact with each other to promote homologous recombination and DNA double-strand breaks repair. The disruption of this interaction has been reported to play a role in tumorigenesis. However, its precise function in HCC remains poorly understood.

Approach and results: We demonstrated that mice with disrupted BRCA1-PALB2 interaction were more susceptible to HCC than wild-type mice. HCC tumors arising from these mice showed plenty of T-lymphocyte infiltration and a better response to programmed cell death 1 (PD-1) antibody treatment. Mechanistically, disruption of the BRCA1-PALB2 interaction causes persistent high level of DNA damage in HCC cells, leading to activation of the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling pathway in both malignant hepatocytes and M1 macrophages in the tumor microenvironment. The activated cGAS-STING pathway induces programmed cell death 1 ligand 1 expression via the STING-interferon regulatory factor 3 (IRF3)-signal transducer and activator of transcription 1 pathway, causing immunosuppression to facilitate tumorigenesis and tumor progression. Meanwhile, M1 macrophages with an activated cGAS-STING pathway could recruit T lymphocytes through the STING-IRF3 pathway, leading to T-lymphocyte infiltration in tumors. After normalizing immune responses by PD-1 antibody treatment, the infiltrating T lymphocytes attack tumor cells rapidly and effectively.

Conclusions: This study reveals that persistent DNA damage caused by a defective BRCA pathway induces tumor immunosuppression and T-lymphocyte infiltration in HCC through the cGAS-STING pathway, providing insight into tumor immune microenvironment remodeling that may help improve HCC response to PD-1 antibody treatment.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • BRCA1 Protein* / metabolism
  • Carcinogenesis
  • Carcinoma, Hepatocellular* / immunology
  • Fanconi Anemia Complementation Group N Protein* / metabolism
  • Immunosuppression Therapy
  • Liver Neoplasms* / immunology
  • Mice
  • Nucleotidyltransferases / metabolism
  • Programmed Cell Death 1 Receptor
  • T-Lymphocytes
  • Tumor Microenvironment

Substances

  • Fanconi Anemia Complementation Group N Protein
  • Nucleotidyltransferases
  • Palb2 protein, mouse
  • Programmed Cell Death 1 Receptor
  • Brca1 protein, mouse
  • BRCA1 Protein